Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresec…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05677490
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 781 more sites in the U.S.
Phase 2, Phase 3 Recruiting NIH
This phase II/III trial compares the addition of nivolumab to the usual treatment of paclitaxel and ramucirumab to paclitaxel and ramucirumab alone in treating patients with gastric or esophageal adenocarcinoma that may have spread from wh…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06203600
Locations: - Baptist Health Medical Center - Little Rock — Little Rock, Arkansas
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- Kaiser Permanente-Anaheim — Anaheim, California
+ 368 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This trial studies how well proton beam radiation therapy compared with intensity modulated photon radiotherapy works in treating patients with stage I-IVA esophageal cancer. Proton beam radiation therapy uses a beam of protons (rather tha…
Sponsor: NRG Oncology
NCT ID: NCT03801876
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mayo Clinic in Arizona — Scottsdale, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
+ 92 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of sonesitatug vedotin in combination with capecitabine with or without rilvegostomig in first-line (1L) Claudin18.2 (CLDN18.2)-positive, human epidermal growth factor recept…
Sponsor: AstraZeneca
NCT ID: NCT07431281
Locations: - Research Site — Phoenix, Arizona
- Research Site — Springdale, Arkansas
- Research Site — Duarte, California
+ 66 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to o…
Sponsor: Pfizer
NCT ID: NCT07392892
Locations: - Rocky Mountain Cancer Centers, LLP — Aurora, Colorado
- Rocky Mountain Cancer Centers, LLP — Boulder, Colorado
- Rocky Mountain Cancer Centers, LLP — Centennial, Colorado
+ 54 more sites in the U.S.
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gast…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07221149
Locations: - Local Institution - 0284 — Phoenix, Arizona
- Local Institution - 0437 — Los Angeles, California
- Local Institution - 0277 — Orange, California
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
This is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of \[¹⁸F\]FAPI-74 PET/CT in the detection of metastatic disease in individuals with pathologically confirmed gastric, gastroesophageal junct…
Sponsor: SOFIE
NCT ID: NCT07217704
Locations: - Helios CR Inc./RadNet — Cerritos, California
- Hoag Memorial Hospital — Irvine, California
- UCLA — Los Angeles, California
+ 7 more sites in the U.S.
Phase 3 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following tre…
Sponsor: Daiichi Sankyo
NCT ID: NCT06644781
Locations: - Providence Medical Foundation — Fullerton, California
- Henry Ford Health System — Detroit, Michigan
- Baptist Cancer Center — Memphis, Tennessee
+ 3 more sites in the U.S.
Phase 2, Phase 3 Recruiting Academic/Other
The goal of this pragmatic, registry-based, randomized clinical trial is to find out if using botulinum toxin (Botox) to help drain the stomach during an esophagectomy works as well as a pyloromyotomy in patients undergoing elective esopha…
Sponsor: The Cleveland Clinic
NCT ID: NCT06721520
Locations: - Cleveland Clinic — Cleveland, Ohio
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Locations: - Research Site 111 — Tucson, Arizona
- Research Site 125 — Los Angeles, California
- Research Site 133 — Los Angeles, California
+ 25 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment wa…
Sponsor: Boehringer Ingelheim
NCT ID: NCT06324357
Locations: - Mayo Clinic-Arizona — Phoenix, Arizona
- The Oncology Institute of Hope and Innovation — Cerritos, California
- Ellison Medical Institute — Los Angeles, California
+ 25 more sites in the U.S.
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2 open-label, multi-center, multi-national study with an initial dose escalation part to determine the recommended Phase II dose (RP2D) of MCLA-158 single agent in patients with mCRC. The dose escalation part has been com…
Sponsor: Merus B.V.
NCT ID: NCT03526835
Locations: - UCSD — La Jolla, California
- USC Norris Comprehensive Cancer Center — Los Angeles, California
- Sharp Healthcare — San Diego, California
+ 20 more sites in the U.S.